KRAS and neoplasm: This initial KRAS SNP has since been found and validated as a marker of risk in multiple tumor types, including colorectal [69,70], head and neck squamous cell carcinoma [71,72], endometrial cancer [73], breast and ovarian cancer [74,75] and others.